Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1007/s00394-007-0655-x. Epub 2007 May 3.

Affiliations

Randomized Controlled Trial

Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?

Dorit Almoznino-Sarafian et al. Eur J Nutr. 2007 Jun.

Abstract

Background: Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF).

Aim of the study: To investigate the relationship, if any, between serum Mg and CRP in HF patients and, concomitantly, to test a hypothesis that Mg supplementation might affect serum CRP levels.

Methods: Serum Mg and CRP were evaluated in 68 patients with chronic systolic HF leading to hospital admission and 65 patients requiring hospitalization for other causes. Following 5 weeks, serum Mg, CRP and intracellular Mg were reevaluated in 17 HF patients after administration of oral Mg citrate 300 mg/day (group A), and 18 untreated HF patients (group B). In order to obtain Gaussian distribution, logarithmic transformation of CRP was performed.

Results: Inverse correlation was found between serum Mg and log CRP (r = -0.28, P = 0.002). Compared to controls, patients with HF demonstrated higher baseline CRP levels, independent of coexisting conditions, and lower serum Mg values. Following Mg treatment, log CRP decreased from 1.4 +/- 0.4 to 0.8 +/- 0.3 in group A (P < 0.001). No significant changes in log CRP were demonstrable in group B. Serum Mg (mmol/l) rose significantly in group A (0.74 +/- 0.04-0.88 +/- 0.08, P < 0.001), and to a lesser extent in group B (0.82 +/- 0.08-0.88 +/- 0.08, P = 0.04). Intracellular Mg significantly increased only in Mg-treated group A (P = 0.01).

Conclusions: Oral Mg supplementation to HF patients significantly attenuates blood levels of CRP, a biomarker of inflammation. Targeting the inflammatory cascade by Mg administration might prove a useful tool for improving the prognosis in HF.

PubMed Disclaimer

References

    1. Clin Cardiol. 1999 Dec;22(12):811-3 - PubMed
    1. J Am Coll Nutr. 2005 Jun;24(3):166-71 - PubMed
    1. Eur Heart J. 1996 Sep;17(9):1345-9 - PubMed
    1. J Mol Cell Cardiol. 1995 Feb;27(2):847 - PubMed
    1. Am Heart J. 1998 Sep;136(3):563-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources